Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient composition

Abstract

A method of preventing, inhibiting and treating a mammal suffering from viral infections using a pharmaceutical micronutrient composition including mixture D is disclosed. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Mixture D and seemed to have beneficial effects to prevent and treat diseases where viruses use the angiotensin converting enzyme 2 (ACE2) receptor on the surface of epithelial cells, endothelial cells and other cell types for viral entry.

What is claimed is: 
     
         1 . A method of treating a mammal using a pharmaceutical micronutrient composition, comprising:
 administering the pharmaceutical micronutrient composition containing an ascorbate in the range of 10 mg to 200,000 mg, N-acetylcysteine in the range of 2 mg to 30,000 mg, theaflavin in the range 5 mg to 3,000 mg, resveratrol in the range of 10 mg to 5,000 mg, cruciferous plant extracts in the range of 5 mg to 5,000 mg, curcumin in the range of 5 mg to 10,000 mg, quercetin in the range of 5 mg to 2,000 mg, naringenin in the range of 5 mg to 3,000 mg, polyphenol extract from green tea in the range of 1 mg to 10,000 mg, brazilin in the range of 1 mg to 5,000 mg and baicalin in the range of 5 mg to 3,000 mg to treat the mammal infected by a virus.   
     
     
         2 . The method of  claim 1 , wherein the ascorbate is at least one of or a combination of a L-ascorbic acid, magnesium ascorbate, calcium ascorbate, ascorbyl palmitate, ascorbyl phosphate, sodium ascorbyl phosphate and another pharmaceutically acceptable form of ascorbate. 
     
     
         3 . The method of  claim 1 , wherein the pharmaceutical micronutrient composition consists of the ascorbate in the range of 10 mg to 200,000 mg, theaflavin in the range 5 mg to 3,000 mg, resveratrol in the range of 10 mg to 5,000 mg, polyphenol extract from green tea in the range of 1 mg to 10,000 mg, cruciferous plant extracts in the range of 5 mg to 5,000 mg, curcumin in the range of 5 mg to 10,000 mg, quercetin in the range of 5 mg to 2,000 mg, naringenin in the range of 5 mg to 3,000 mg, and baicalin in the range of 5 mg to 3,000 mg. 
     
     
         4 . The method of  claim 1 , wherein the pharmaceutical micronutrient composition consists of the ascorbate in the range of 10 mg to 200,000 mg, N-acetylcysteine in the range of 2 mg to 30,000 mg, resveratrol in the range of 10 mg to 5,000 mg, polyphenol extract from green tea in the range of 1 mg to 10,000 mg, cruciferous plant extracts in the range of 5 mg to 5,000 mg, curcumin in the range of 5 mg to 10,000 mg, quercetin in the range of 5 mg to 2,000 mg, naringenin in the range of 5 mg to 3,000 mg, and baicalin in the range of 5 mg to 3,000 mg. 
     
     
         5 . The method of  claim 1 , wherein the pharmaceutical micronutrient composition consists of the ascorbate in the range of 10 mg to 200,000 mg, N-acetylcysteine in the range of 2 mg to 30,000 mg, theaflavin in the range 5 mg to 3,000 mg, resveratrol in the range of 10 mg to 5,000 mg, cruciferous plant extracts in the range of 5 mg to 5,000 mg, curcumin in the range of 5 mg to 10,000 mg, quercetin in the range of 5 mg to 2,000 mg, naringenin in the range of 5 mg to 3,000 mg, and baicalin in the range of 5 mg to 3,000 mg. 
     
     
         6 . The method of  claim 1 , wherein the baicalein is from natural and synthetic source, theaflavin is from a plant source, curcumin is from a plant source, resveratrol is from a plant source, quercetin is from a plant source, cruciferous plant extract is from a plant source, naringenin is from a plant source, and N-acetylcysteine is from a plant source. 
     
     
         7 . The method of  claim 1 , wherein a viral infectious disease is treated using the pharmaceutical micronutrient composition. 
     
     
         8 . The method of  claim 1 , wherein the human and other species are treated for a viral infection by administering the pharmaceutical micronutrient composition. 
     
     
         9 . The method of  claim 8 , wherein the viral infection or viral disease is that which uses a cellular receptor for a viral entry on a surface of an epithelial cells, endothelial cells or other cell types. 
     
     
         10 . The method of  claim 9 , wherein the viral infection or viral disease is that which uses an angiotensin converting enzyme 2 (ACE2) receptor on the surface of an epithelial cell, endothelial cell and other cell types, for the viral entry. 
     
     
         11 . The method of  claim 10 , wherein the pharmaceutical micronutrient composition is used to treat the human and other species with severe acute respiratory syndrome-related to a coronaviruses (SARS-CoV-1), SARS-CoV2 and their variants or mutants that use angiotensin converting enzyme 2 (ACE2) receptors on the surface of epithelial cells, endothelial cells and other cell types, for viral entry. 
     
     
         12 . The method of  claim 11 , wherein the pharmaceutical micronutrient composition is used to treat the human and other species with a Middle East respiratory syndrome-related coronavirus (MERS-CoV), and its variants or mutants that use the angiotensin converting enzyme 2 (ACE2) receptor on the surface of epithelial cells, endothelial cells and other cell types, for viral entry. 
     
     
         13 . A method of treating a mammal, comprising:
 formulating a pharmaceutical micronutrient composition consisting of an ascorbate in the range of 10 mg to 200,000 mg, N-acetylcysteine in the range of 2 mg to 30,000 mg, theaflavin in the range of 5 mg to 3,000 mg, resveratrol in the range of 10 mg to 5,000 mg, cruciferous plant extracts in the range of 5 mg to 5,000 mg, curcumin in the range of 5 mg to 10,000 mg, quercetin in the range of 5 mg to 2,000 mg, naringenin in the range of 5 mg to 3,000 mg, and baicalin in the range of 5 mg to 3,000 mg; and   administering the pharmaceutical micronutrient composition to treat a human and other mammals with a Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS CoV, SARS-CoV2 and their variants or mutants that use the angiotensin converting enzyme 2 (ACE2) receptor on the surface of epithelial cells, endothelial cells and other cell types for viral entry.   
     
     
         14 . The method of  claim 13 , wherein the pharmaceutical micronutrient composition is formulated as an oral, non-invasive peroral, topical (for example, transdermal), enteral, transmucosal, targeted delivery, sustained-release delivery, delayed-release, pulsed-release and parenteral form. 
     
     
         15 . The pharmaceutical micronutrient composition according to  claim 13 , wherein the pharmaceutical micronutrient composition is introduced with a food, drinking water, tube feeding, and as an adjunct to other medicinal treatment.